1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Drugs In Development, 2022, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 4, 4, 4, 1, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Phase 0 stages comprises 1 molecules, respectively.
Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Dermatomyositis - Overview
- Dermatomyositis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Dermatomyositis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Dermatomyositis - Companies Involved in Therapeutics Development
- Adienne Pharma & Biotech SA
- Alexion Pharmaceuticals Inc
- Argenx SE
- Avotres Inc
- Cellular Biomedicine Group Ltd
- CSL Ltd
- Ermium Therapeutics SAS
- Fresh Tracks Therapeutics Inc
- Galapagos NV
- GNI Group Ltd
- Horizon Therapeutics Plc
- Juventas Cell Therapy Ltd
- Kezar Life Sciences Inc
- NovelMed Therapeutics Inc
- Paean Biotechnology Inc
- Pfizer Inc
- Priovant Therapeutics Inc
- Santhera Pharmaceuticals Holding AG
- Dermatomyositis - Drug Profiles
- AVT-001 - Drug Profile
- Product Description
- Mechanism Of Action
- begelomab - Drug Profile
- Product Description
- Mechanism Of Action
- Biologic for Central Nervous System, Infectious Disease, Musculoskeletal Disorders and Respiratory - Drug Profile
- Product Description
- Mechanism Of Action
- brepocitinib tosylate - Drug Profile
- Product Description
- Mechanism Of Action
- CNCT-19 - Drug Profile
- Product Description
- Mechanism Of Action
- CXCR4 biased agonist - Drug Profile
- Product Description
- Mechanism Of Action
- daxdilimab - Drug Profile
- Product Description
- Mechanism Of Action
- efgartigimod alfa - Drug Profile
- Product Description
- Mechanism Of Action
- FRTX-10 - Drug Profile
- Product Description
- Mechanism Of Action
- gefurulimab - Drug Profile
- Product Description
- Mechanism Of Action
- GLPG-3667 - Drug Profile
- Product Description
- Mechanism Of Action
- immune globulin (human) - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibodies for Dermatomyositis - Drug Profile
- Product Description
- Mechanism Of Action
- ONX-0914 - Drug Profile
- Product Description
- Mechanism Of Action
- PF-06823859 - Drug Profile
- Product Description
- Mechanism Of Action
- pirfenidone - Drug Profile
- Product Description
- Mechanism Of Action
- PN-101 - Drug Profile
- Product Description
- Mechanism Of Action
- ravulizumab LA - Drug Profile
- Product Description
- Mechanism Of Action
- RD-1301 - Drug Profile
- Product Description
- Mechanism Of Action
- tofacitinib citrate ER - Drug Profile
- Product Description
- Mechanism Of Action
- vamorolone - Drug Profile
- Product Description
- Mechanism Of Action
- zetomipzomib - Drug Profile
- Product Description
- Mechanism Of Action
- Dermatomyositis - Dormant Projects
- Dermatomyositis - Discontinued Products
- Dermatomyositis - Product Development Milestones
- Featured News & Press Releases
- May 03, 2022: Kezar announces topline results from PRESIDIO trial of zetomipzomib for the treatment of dermatomyositis and polymyositis
- Aug 23, 2021: Kezar Life Sciences announces completion of enrollment of its Phase 2 PRESIDIO clinical trial of KZR-616 in polymyositis and dermatomyositis
- May 26, 2021: Kezar Life Sciences to host virtual MISSION phase 1b data update call at EULAR 2021
- Nov 05, 2020: Kezar highlights broad therapeutic potential of KZR-616 during ACR Convergence 2020
- Oct 23, 2020: Kezar Life Sciences announces Orphan Drug Designations for KZR-616 for the treatment of polymyositis and dermatomyositis
- Sep 10, 2020: Kezar Life Sciences to present at The Myositis Association International Annual Patient Conference and the Pan-American Congress of Rheumatology
- Sep 09, 2020: Avotres received the approval letter from the IRB to initiate human ex vivo studies of AVT001
- Jun 06, 2018: GNI Group Initiates Etuary Phase III Trial in China for CTD-ILD
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Dermatomyositis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Dermatomyositis - Pipeline by Adienne Pharma & Biotech SA, 2022
- Dermatomyositis - Pipeline by Alexion Pharmaceuticals Inc, 2022
- Dermatomyositis - Pipeline by Argenx SE, 2022
- Dermatomyositis - Pipeline by Avotres Inc, 2022
- Dermatomyositis - Pipeline by Cellular Biomedicine Group Ltd, 2022
- Dermatomyositis - Pipeline by CSL Ltd, 2022
- Dermatomyositis - Pipeline by Ermium Therapeutics SAS, 2022
- Dermatomyositis - Pipeline by Fresh Tracks Therapeutics Inc, 2022
- Dermatomyositis - Pipeline by Galapagos NV, 2022
- Dermatomyositis - Pipeline by GNI Group Ltd, 2022
- Dermatomyositis - Pipeline by Horizon Therapeutics Plc, 2022
- Dermatomyositis - Pipeline by Juventas Cell Therapy Ltd, 2022
- Dermatomyositis - Pipeline by Kezar Life Sciences Inc, 2022
- Dermatomyositis - Pipeline by NovelMed Therapeutics Inc, 2022
- Dermatomyositis - Pipeline by Paean Biotechnology Inc, 2022
- Dermatomyositis - Pipeline by Pfizer Inc, 2022
- Dermatomyositis - Pipeline by Priovant Therapeutics Inc, 2022
- Dermatomyositis - Pipeline by Santhera Pharmaceuticals Holding AG, 2022
- Dermatomyositis - Dormant Projects, 2022
- Dermatomyositis - Discontinued Products, 2022
- Number of Products under Development for Dermatomyositis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adienne Pharma & Biotech SA
- Alexion Pharmaceuticals Inc
- Argenx SE
- Avotres Inc
- Cellular Biomedicine Group Ltd
- CSL Ltd
- Ermium Therapeutics SAS
- Fresh Tracks Therapeutics Inc
- Galapagos NV
- GNI Group Ltd
- Horizon Therapeutics Plc
- Juventas Cell Therapy Ltd
- Kezar Life Sciences Inc
- NovelMed Therapeutics Inc
- Paean Biotechnology Inc
- Pfizer Inc
- Priovant Therapeutics Inc
- Santhera Pharmaceuticals Holding AG
